Key result
CRT linked to improved clinical outcomes and lower mortality vs ICD in heart failure.
Why the study?
Prognosis in heart failure is poor with annual mortality ranging from 15-60%, and this study aimed to determine the effects of cardiac resynchronization therapy in patients with moderate to severe heart failure.
Observational (n=140)
No
Answers are grounded in this paper and cite their sources.
CRT effects in moderate-severe HF are hypothesis-generating; leaves open need for randomized confirmation before practice change.
Prognosis in heart failure (HF) is poor and mortality widely ranges - 15-60% per year. Cardiac resynchronization therapy (CRT) is a therapeutic concept for patients who have NYHA III or IV class, LVEF ≤ 35%, left bundle branch block with wide QRS ≥ 120ms and ventricular dyssynchrony on optimal medical therapy. The aim of the study was to determine the effects of resynchronization therapy in patients with moderate to severe HF. In our study, 140 patients with HF were treated with different modalities of therapy in the Clinical Centre Niš. The first group of patients received CRT, and the second, control group were HF patients without echo criteria for CRT. In the control group, 36 patients received an implantable cardioverter-defibrillator (ICD). Results of the study showed that resynchronization therapy in patients with HF improves different parameters: clinical symptoms, echocardiographic parameters, decreases QRS duration, increases 6-minute walk test distance and decreases mortality rate. The benefit of cardiac resynchronization therapy in combination with optimal medical therapy is proven to be beneficial in patients with HF and asynchrony. CRT improved clinical symptoms of heart failure and had influence on disease progression.
No takes yet. Share an insight, caveat, or question.
Kostić et al. (2013) conducted an observational in Moderate to severe heart failure (n=140). Cardiac resynchronization therapy (CRT) vs. Heart failure patients without echocardiographic criteria for CRT (including 36 with ICD) was evaluated on Clinical symptoms, echocardiographic parameters, QRS duration, 6-minute walk test distance, and mortality rate. Cardiac resynchronization therapy in 140 heart failure patients improved clinical symptoms, 6-minute walk distance, echo parameters, QRS duration, and mortality vs controls (36 with ICD).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: